CLINICAL STUDY

Relationship between doses of antihypertensive drugs and left ventricular mass index changes in hemodialysis patients in a Japanese cohort

Fumiya Kitamura\textsuperscript{a}, Makoto Yamaguchi\textsuperscript{a}, Takayuki Katsuno\textsuperscript{a}, Hironobu Nobata\textsuperscript{a}, Shiho Iwagitsu\textsuperscript{a}, Hirokazu Sugiyama\textsuperscript{b}, Hiroshi Kinashi\textsuperscript{b}, Shogo Banno\textsuperscript{b}, Masahiko Ando\textsuperscript{b}, Yoko Kubo\textsuperscript{b}, Yasumasa Kawade\textsuperscript{c}, Iwashima Shigeji\textsuperscript{d}, Yutaka Ito\textsuperscript{c}, Takuji Ishimoto\textsuperscript{f} and Yasuhiko Ito\textsuperscript{a}

\textsuperscript{a}Department of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan; \textsuperscript{b}Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; \textsuperscript{c}Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan; \textsuperscript{d}Suzuka Kidney Clinic, Josuikai Group, Suzuka, Japan; \textsuperscript{e}Yokkaichi Kidney Clinic, Josuikai Group, Yokkaichi, Japan; \textsuperscript{f}Department of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan

\section*{ABSTRACT}
Left ventricular hypertrophy commonly occurs in dialysis patients and is associated with a risk of developing cardiovascular disease events and all-cause mortality. Although hypertension treatment reduces left ventricular mass index (LVMI) in hemodialysis patients, the relationships of prescription pattern, dose, and changes in the dose of antihypertensive drugs with LVMI have not been completely elucidated. Here, we hypothesized that volume reduction would lead to a decrease in the antihypertensive drug dose and subsequently to a reduction in LVMI; conversely, fluid retention would lead to an increase in the antihypertensive drug use and, subsequently, to LVMI progression. To assess this hypothesis, we investigated the relationship between changes in the dose of antihypertensive drugs and subsequent changes in LVMI in 240 patients who had just started hemodialysis using a retrospective hemodialysis cohort in Japan. Using multiple linear regression analysis, we assessed the association between changes in the antihypertensive drug dose over 1 year after hemodialysis initiation and changes in LVMI during this period. A decrease and an increase in the antihypertensive drug dose were significantly associated with a reduction in LVMI (vs. no change; \( \beta = -17.386, p < .001 \)) and LVMI progression (vs. no change; \( \beta = 16.192, p < .001 \)), respectively. In conclusion, our findings suggested that volume reduction, leading to a decrease in the use of antihypertensive drugs, is a therapeutic strategy in patients undergoing hemodialysis to prevent LVMI progression.

\section*{Introduction}
Cardiovascular diseases (CVDs) are the most frequent causes of death among hemodialysis (HD) patients \cite{1,2}. Left ventricular hypertrophy (LVH) commonly occurs in dialysis patients and is associated with the risk of developing CVD events and all-cause mortality \cite{3,4}. The mechanisms underlying the development and progression of LVH are multifactorial and include hypertension, volume overload, obesity, arterial stiffening, anemia, and metabolic and humoral abnormalities \cite{5}. Previous studies have shown that hypertension treatment reduces LVH, leading to good prognosis in the general population \cite{6} and HD patients \cite{7–10}. The treatment strategy for hypertension in HD patients includes achieving a euvolemic state and using antihypertensive medications. Targeting dry weight with euvolemia may facilitate high blood pressure (BP) control, leading to a reduction in the use of antihypertensive drugs \cite{11–14}. However, several antihypertensive medications (ranging from 2.8 to 4.0) are often prescribed to HD patients to lower BP \cite{15}. One reason underlying this decision is the lack of a definite index for controlling the volume status, leading to difficulty in achieving euvolemia and, consequently, a reduction in the use of antihypertensive drugs. Furthermore, it is unclear whether extracellular fluid overload can cause LVH progression when BP is controlled by antihypertensive drugs. To date, no previous studies have focused
on the relationship between the prescription pattern of antihypertensive drugs, dose, and changes in the antihypertensive medication dose and left ventricular (LV) structure.

In the present study, we hypothesized that achieving euvolemma would lead to a decrease in the dose of antihypertensive drugs and, subsequently, to a reduction in LV mass index (LVMI). Conversely, fluid retention would lead to an increase in the use of antihypertensive drugs and, subsequently, to LVMI progression. To assess this hypothesis, we first investigated the association between the dose of antihypertensive drugs at the time of HD initiation and LVMI. Then, we examined the changes in the dose of antihypertensive drugs and subsequent LVMI changes using a retrospective longitudinal cohort that included hypertensive patients who had just started HD in Japan.

**Materials and methods**

**Participants**

This cohort study included adult hypertensive HD patients who had received at least one antihypertensive drug upon starting HD and had undergone echocardiography at least twice during an observation period of approximately 1 year. Among 321 patients who had newly started HD (from 2009 to 2014) in two HD centers of the Josui group in Japan, we excluded those who had not taken antihypertensive drugs (n = 9) and those who could not be reexamined with another echocardiography (n = 58). The first echocardiography was performed within 3 months after HD initiation, whereas the second echocardiography was carried out after 1 year. Finally, after excluding 14 patients with missing echocardiographic data, a total of 240 patients were included in the present study (Figure 1). All data were fully anonymized and the ethics committee of the Josui group (approval number: 19-1) waived the requirement for patient informed consent owing to the retrospective nature of this study. The anonymous data set are shown in Supplementary Table 1.

**Measurements**

Clinical data were obtained from medical records. The following baseline characteristics were defined at the time of the first echocardiography: age, sex, the primary cause of end-stage renal disease, comorbidities, diabetes, history of previous CVD including coronary heart disease (angina and myocardial infarction), arrhythmia including atrial fibrillation, cardiac arrest, congestive heart failure, and valvular heart disease. We also considered other cardiovascular conditions, such as both pre- and post-dialysis BP, body weight, vascular access type (including arteriovenous fistula or prosthetic graft), weekly erythropoiesis-stimulating agents, dosage, single-pool Kt/V, duration of dialysis treatment (hours per week), and serum laboratory data (including hemoglobin, serum albumin, C-reactive protein, serum creatinine, blood urea nitrogen, serum calcium, serum phosphate, intact parathyroid hormone, and serum

---

**Figure 1.** Flow diagram of patient selection.
Table 1. Baseline characteristics at the time of the first cardiac echocardiography (n = 240).

| Variables | Overall (n = 240) | DDD ≤ 1 (n = 20) | 1 < DDD ≤ 3 (n = 159) | DDD > 3 (n = 61) | p-value |
|-----------|-----------------|-----------------|---------------------|-----------------|--------|
| Age (year) | 66 (58–74) | 64 (56–74) | 66 (57–73) | 66 (61–75) | .588 |
| Male (N (%)) | 158 (65.8) | 11 (55.0) | 105 (66.0) | 42 (68.9) | .524 |
| BMI (kg/m²) | 21.8 (19.6–24.4) | 21.8 (19.5–26.6) | 21.1 (19.3–23.5) | 22.4 (21.2–25.4) | .012 |
| Comorbidities | | | | | |
| Diabetes mellitus | 127 (52.9) | 11 (55.0) | 87 (54.7) | 29 (47.5) | .622 |
| Cause of kidney disease | 122 (50.8) | 11 (55.0) | 82 (51.6) | 29 (47.5) | .637 |
| Glomerulonephritis | 34 (14.2) | 2 (10.0) | 25 (15.7) | 7 (11.5) | |
| Hypertensive nephrosclerosis | 21 (8.8) | 0 (0.0) | 13 (8.2) | 8 (13.1) | |
| Others | 63 (26.3) | 7 (35.0) | 39 (24.5) | 17 (27.9) | |
| Hemoglobin (g/dL) | 10.9 (10.5–11.4) | 11.1 (10.9–11.3) | 10.9 (10.5–11.4) | 10.9 (10.4–11.5) | .813 |
| Serum albumin (g/L) | 3.7 (3.4–3.9) | 3.8 (3.5–4.1) | 3.7 (3.4–3.9) | 3.7 (3.4–3.8) | .450 |
| Serum calcium (mg/dL) | 4.4 (3.9–4.9) | 4.5 (4.1–4.9) | 4.4 (3.9–4.9) | 4.3 (3.6–4.8) | .263 |
| Serum creatinine (mg/dL) | 19.3 (7.8–10.9) | 9.0 (8.3–10.5) | 9.6 (8.0–11.3) | 8.7 (7.3–10.7) | .087 |
| Blood urea nitrogen (mg/dL) | 55 (49–64) | 56 (49–63) | 56 (49–63) | 57 (49–65) | .945 |
| Serum magnesium (mg/dL) | 2.5 (2.3–2.6) | 2.4 (2.2–2.6) | 2.5 (2.3–2.6) | 2.5 (2.3–2.7) | .334 |
| Serum calcium (mg/dL) | 8.9 (8.6–9.3) | 8.8 (8.5–9.1) | 8.9 (8.5–9.3) | 9.0 (8.7–9.4) | .247 |
| Serum phosphate (mg/dL) | 4.7 (4.1–5.4) | 5.0 (4.6–1.3) | 4.6 (4.1–5.3) | 4.7 (4.2–5.5) | .290 |
| Serum intact PTH (pg/mL) | 105 (70–170) | 107 (72–148) | 108 (66–177) | 103 (76–160) | .727 |
| CRP (mg/dL) | 0.9 (0.05–23) | 0.08 (0.05–14) | 0.07 (0.05–24) | 0.12 (0.06–33) | .122 |
| LDL-cholesterol (mg/dL) | 81 (66–99) | 78 (68–91) | 80 (62–101) | 87 (70–100) | .393 |
| Antihypertensive drugs | | | | | |
| Dose of antihypertensive drugs | 3 (2–3.5) | 1 (1–1) | 2.5 (2–3) | 4 (3.8–4) | <.001 |
| RAS blocker | 217 (90.4) | 17 (85.0) | 143 (89.9) | 57 (93.4) | .506 |
| Calcium channel blocker | 226 (94.2) | 16 (80.0) | 152 (95.6) | 58 (95.1) | .018 |
| β-blocker | 25 (10.4) | 4 (20.0) | 5 (3.1) | 16 (26.2) | <.001 |
| Other drugs | 13 (5.4) | 0 (0.0) | 4 (2.5) | 9 (14.8) | <.001 |
| Vitamin D | 213 (88.8) | 17 (85.0) | 145 (91.2) | 51 (83.6) | .241 |
| Phosphate binder | 225 (93.8) | 18 (90.0) | 148 (93.1) | 59 (96.7) | .468 |
| HMG-CoA reductase inhibitor | 52 (21.7) | 3 (15.0) | 28 (17.6) | 21 (34.4) | .014 |
| Calcimimetics | 38 (15.4) | 3 (15.0) | 27 (17.0) | 8 (13.1) | .777 |
| Dose of erythropoietin (U/week) | 3750 (2250–6000) | 3375 (1688–6000) | 3000 (2250–5000) | 3750 (2250–7500) | .666 |
| Cardiothoracic ratio (%) | 49 (47–54) | 45 (42–48) | 48 (46–53) | 51 (48–55) | <.001 |

AVF: arteriovenous fistula; AVG: arteriovenous graft; BMI: body mass index; CRP: C-reactive protein; DDD: defined daily dose; PTH: parathyroid hormone; RAS: renin-angiotensin system. Medians (interquartile ranges), categorical values are expressed as numbers (proportions).

magnesium levels). Chest radiographs were used to examine pre-dialysis after a 2-day interdialytic interval in an upright posterior-anterior view, according to the Japanese guidelines [16]. Cardiothoracic ratio, the maximal horizontal diameter of the heart divided by the horizontal inner width of the rib cage, was measured.

**Antihypertensive drugs during the observation period**

Prescriptions of antihypertensive medications were obtained from medical records including the renin-angiotensin system (RAS) blockers (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers), β-blockers (selective, nonselective, and α- and β-blocker agents), calcium channel blockers (dihydropyridines and non-dihydropyridines), and centrally acting antiadrenergic agents. Each daily dose was converted to a standardized daily dose based on the corresponding defined daily dose (DDD) both at baseline and 1 year, as proposed by previous studies [17,18].

For example, when a person is receiving valsartan 80 mg (DDD = 80 mg) and amlodipine 10 mg (DDD = 5 mg) per day, he/she is reaching a total score of 3 DDGs.

**Echocardiography**

Transthoracic echocardiography was performed according to the American Society of Echocardiography guidelines at baseline and after 1 year [19]. The first echocardiography was performed within 3 months after HD initiation (median of 1.2 [8–14] months) in all patients.
LV mass was calculated using a formula recommended by the American Society of Echocardiography [19] and indexed according to the body surface area. LVH was defined as LVMI by a body surface area of $\geq 115$ and $\geq 95$ g/m² in men and women, respectively [20]. LV outflow velocity was obtained from the apical position. Early and atrial mitral inflow velocities were obtained with a signal positioned at the tip of the mitral leaflets. LV ejection fraction was calculated by the modified biplane (Simpson method) [21].

**Exposure and outcomes**

The primary exposure of interest was the change in DDD drugs over 1 year after starting HD. The primary outcome of interest was the change in LVMI (per g/m²) over 1 year.

**Statistical analyses**

Patients were stratified into three DDD categories at baseline, namely $\leq 1$, 1–3, and $>3$, as previously reported [22]. The baseline characteristics, echocardiography results, changes in LVMI, cardiothoracic ratio, and pre-dialysis BP over 1 year were compared among these three groups using the Kruskal–Wallis test followed by Mann–Whitney post-hoc analysis with Bonferroni correction or Pearson’s chi-square test. To determine the factors that were independently associated with the outcome, we examined the change in LVMI over a period of 1 year using univariate linear regression analysis. Multiple linear regression analysis for the LVMI changes was performed with adjustment for all clinical factors that were included in the univariate model. The participants were divided into the following three categories according to the DDD changes over 1 year after HD initiation: decrease, no change, or increase. In each group, the LVMI changes were assessed using the paired t-test. The level of statistical significance was set at $p < .05$. All statistical analyses were performed using JMP version 14.0.0 (SAS Institute, Cary, NC, USA), SAS version 9.4 (SAS Institute, Inc, Cary, NC), and STATA version 13.0 (StatCorp LP, College Station, TX, USA).

**Results**

**Baseline characteristics and LV measurements of study participants**

The baseline characteristics of the study participants and their LV measurements were stratified according to the three DDD categories summarized in Tables 1 and 2, respectively. The present study included 20 (8.3%; DDD $\leq 1$), 159 (66.3%; 1 < DDD $\leq 3$), and 61 patients (25.4%; DDD $> 3$). Patients with higher DDD had also higher body mass index ($p = .032$), level of the LVMI/body surface area ($p < .001$), the prevalence of LVH ($p < .001$), cardiothoracic ratio ($p < .001$), and prevalence of HMG-CoA reductase inhibitor use ($p = .014$) compared to those with lower DDD. The other findings were comparable among the groups.

**Antihypertensive drugs**

At baseline, 217 (90.4%) and 226 (94.2%) participants had RAS and calcium channel blockers, respectively. The proportion of RAS and calcium channel blockers was comparable between the groups. Over a period of 1 year after HD initiation, in the DDD $\leq 1$ group, eight (40%) patients demonstrated an increase in DDD. In the DDD $> 3$ group, 40 (80.3%) patients had a decrease in

| Table 2. LV measurements and indices at baseline. |
|-----------------------------------------------|
| Variables                  | Overall ($n = 240$) | DDD $\leq 1$ ($n = 20$) | 1 < DDD $\leq 3$ ($n = 159$) | DDD $> 3$ ($n = 61$) | p-value |
| LV measurements and indices |                      |                          |                              |                            |         |
| LVMI (g/m²)                | 119 (99–145)        | 75 (67–88)               | 116 (99–135)                 | 146 (119–172)              | $< .001$|
| LVH (%)                    | 151 (62.9)          | 0 (0.0)                  | 95 (59.8)                    | 56 (91.8)                  | $< .001$|
| LVEF (%)                   | 69 (63–75)          | 71 (63–78)               | 69 (64–75)                   | 69 (62–74)                 | .263    |
| AOD (mm)                   | 31 (27–34)          | 30 (26–32)               | 30 (27–34)                   | 32 (29–35)                 | .098    |
| LAD (mm)                   | 36 (32–39)          | 31 (25–36)               | 35 (31–39)                   | 37 (35–42)                 | $< .001$|
| LVIDd (mm)                 | 42 (37–47)          | 34 (32–38)               | 43 (37–47)                   | 44 (40–52)                 | $< .001$|
| LVIDs (mm)                 | 26 (22–30)          | 21 (20–22)               | 26 (22–30)                   | 27 (25–30)                 | $< .001$|
| IVS (mm)                   | 12 (11–14)          | 11 (9–13)                | 12 (11–14)                   | 13 (12–15)                 | $< .001$|
| LVFW (mm)                  | 12 (11–13)          | 11 (10–13)               | 12 (11–13)                   | 13 (12–14)                 | $< .001$|
| Mitral inflow E (cm/s)     | 65 (53–81)          | 74 (58–83)               | 66 (51–83)                   | 63 (53–74)                 | .292    |
| Mitral inflow A (cm/s)     | 88 (78–104)         | 90 (78–96)               | 87 (77–105)                  | 91 (78–100)                | .795    |
| E/A                        | .72 (.60–.86)       | .95 (.70–1.11)           | .72 (.59–.85)                | .66 (.57–.76)              | .018    |
| E/e                         | 12.3 (9.1–14.7)     | 9.9 (8.4–17.2)           | 12.5 (9.2–13.8)              | 12.2 (8.8–15.7)            | .932    |
| Left atrial volume index (ml/m²) | 16.8 (13.5–21.5) | 15.5 (12.5–18.7)         | 17.2 (13.3–22.3)             | 16.6 (14.1–20.0)           | .689    |

AOD: aortic end-diastolic diameter; E/A: the ratio of left ventricular early-diastolic inflow velocity (E) to atrial systolic velocity (A); e’: early-diastolic mitral annular velocity; E/e’: the ratio of E to e’; EF: ejection fraction; IVS: interventricular septum; LAD: left atrial dimension; LV: left ventricular; LVIDd: left ventricular internal dimension in diastole; LVIDs: left ventricular internal dimension in systole; LVH: LV hypertrophy; LVMI: LV mass index; LVFW: left ventricular posterior wall thickness. Medians (interquartile ranges), categorical values are expressed as numbers (proportions).
with decreased DDD, LVMI was significantly decreased and decrease in DDD over 1 year) (Figure 2). In patients according to the DDD changes (increase, no change, decrease in DDD), LVMI was significantly decreased in patients with a higher DDD showed a significant reduction over a period of 1 year. However, there was no significant change in pre-dialysis BP (p = .284) and post-dialysis weight (p = .058).

Changes in LVMI, cardiothoracic ratio, pre-dialysis BP between the DDD groups (DDD ≤ 1, 1 < DDD ≤ 3, and DDD > 3)

LVMI, cardiothoracic ratio, pre-dialysis BP, and post-dialysis weight in the three groups at baseline and after 1 year, as well as the changes over 1 year, are presented in Table 4. Compared to patients with a lower DDD, those with a higher DDD showed a significant reduction in LVMI (p < .001) and cardiothoracic ratio (p = .033) over a period of 1 year. However, there was no significant change in pre-dialysis BP (p = .284) and post-dialysis weight (p = .058).

Changes in LVMI, post-dialysis weight, cardiothoracic ratio, and pre-dialysis BP between groups of DDD change (decrease, no change, and increase in DDD)

We compared the changes in the LVMI stratified according to the DDD changes (increase, no change, and decrease in DDD over 1 year) (Figure 2). In patients with decreased DDD, LVMI was significantly decreased from 130 g/m² (interquartile range [IQR], 111–158 g/m²) at baseline to 108 g/m² (IQR, 89–131 g/m²) at 1 year (p = .017). In patients exhibiting no change in DDD, no significant change in LVMI was observed (LVMI was 118 g/m² [IQR, 99–143 g/m²] at baseline and 119 g/m² [IQR, 99–143 g/m²] after 1 year) (p = .992). In patients with increased DDD, LVMI was significantly increased from 101 g/m² (IQR, 85–117 g/m²) at baseline to 122 g/m² (IQR, 110–138 g/m²) at 1 year (p = .008).

A significant decrease in the post-dialysis weight over the period of 1 year was observed in patients with decreased DDD compared to that in patients with increased DDD (p = .002) (Supplementary Table 2). Furthermore, a decrease in the cardiothoracic ratio over the period of 1 year was more frequently observed in patients with decreased than in those with increased DDD (p = .045) (Supplementary Table 2). No significant differences were observed in pre-dialysis BP, at baseline, 1 year, and over 1 year (p = .659, .180, and .252, respectively) (Supplementary Table 2).

Clinical factors affecting LVMI changes

Univariate analysis revealed that higher LVMI and DDD at baseline were associated with a decrease in LVMI.
A decrease and an increase in DDD over a period of 1 year were significantly associated with reduced (\( p < .001 \)) and increased LVMI (\( p < .001 \)), respectively (Table 5). Furthermore, a change in the cardiothoracic ratio was significantly associated with a change in LVMI (\( p < .001 \)).

Multiple linear regression analysis was performed using all covariates that were assessed in the univariate model. It revealed that higher LVMI and cardiothoracic ratio values at baseline were associated with a decrease in LVMI (\( p < .001 \)). An increase and a decrease in DDD over a period of 1 year were significantly associated
with LVMI changes (p < .001), in addition to changes in systolic BP (p < .001) and cardiothoracic ratio (p < .001) (Table 6).

**Discussion**

This retrospective longitudinal cohort study showed that a change in the dose of antihypertensive drugs was significantly associated with changes in LVMI over a period of 1 year after HD initiation. Decreased antihypertensive drug use was significantly associated with reduced LVMI. Conversely, an increase in the use of antihypertensive drugs was significantly associated with LVMI progression. These results indicated that patients with decreased use of antihypertensive drugs became euvoletic, which led to reduced LVMI. Conversely, those who increased the use of antihypertensive drugs proceeded to volume retention, leading to LVMI progression. To the best of our knowledge, this was the first study evaluating the relationship between changes in the dose of antihypertensive drugs and changes in LVMI.

Previous observational cohort studies evaluated the predictors of LVH in dialysis patients. Higher pre-dialysis systolic BP [23], pre-dialysis mean arterial pressure [24], and intradialytic systolic BP [25] were associated with LVH. However, these studies did not evaluate the relationship between the prescription pattern of antihypertensive drugs (time-course changes in the dose of hypertensive drugs) and LVH progression.

Based on the method of control of BP in dialysis patients, a retrospective study reported that patients in the hypervolemic state had poor BP control, suggesting that antihypertensive drugs are ineffective in the hypervolemic state [12]. In contrast, the strict volume control group exhibited good BP control [13]. These results indicated that volume control is an important strategy for BP control in dialysis patients.

In the present study, patients with an increased use of antihypertensive drugs might have experienced hidden volume retention even when no obvious findings of volume overload were observed, leading to a greater effect on LVH progression than that in patients with a decreased dose of antihypertensive drugs. With respect to the volume status influence on LVMI, a cross-sectional study [14] reported that LVMI was lower in patients who demonstrated extracellular fluid volume reduction by dietary salt restriction and persistent ultrafiltration than in those who used an antihypertensive medication strategy despite the lack of a significant difference in BP between the groups. These findings suggested that the hypervolemic state may alter LVMI progression. However, due to the cross-sectional study design, causal relationships between the volume control and LVH reduction could not be determined. A randomized controlled study reported that the strict volume control group exhibited a reduction in BP and LVMI regression compared with the control group [26]. However, this study was based entirely on middle-aged patients (age, 51.6 ± 12.3 years), and the proportion of prescribed antihypertensive drugs was lower (23%).

| Candidate variables | β   | SE  | T    | p-value |
|---------------------|-----|-----|------|---------|
| Age                 | −0.042 | 0.114 | −0.370 | 0.712 |
| Male sex (vs. female) | −2.968 | 1.476 | −2.010 | 0.046 |
| Diabetes mellitus (vs. non-diabetes mellitus) | 1.375 | 1.476 | 0.970 | 0.334 |
| BMI (kg/m²)         | −1.190 | 0.440 | −2.40 | 0.066 |
| Pre-dialysis systolic BP (mmHg) | −0.260 | 0.093 | −2.210 | 0.006 |
| Change in systolic BP (from baseline to 1 year) (mmHg) | 0.266 | 0.0654 | 4.080 | <.001 |
| Hemoglobin (g/dL)   | 0.446 | 1.828 | 0.240 | 0.808 |
| Serum calcium (mg/dL) | −1.184 | 2.398 | −0.490 | 0.622 |
| Serum phosphate (mg/dL) | −0.429 | 1.316 | −0.330 | 0.745 |
| Serum intact PTH (pg/mL) | 0.019 | 0.014 | 1.350 | 0.177 |
| LDL-cholesterol (mg/dL) | 0.063 | 0.055 | 2.930 | 0.004 |
| Change in the cardiothoracic ratio over a period of 1 year (%) | 0.104 | 0.934 | 1.140 | 0.256 |
| Changes in post-dialysis weight over a period of 1 year (kg) | 0.125 | 0.373 | 3.330 | 0.001 |
| AVF (vs. AVG)       | −0.668 | 2.209 | −0.300 | 0.763 |
| LVMI (g/m²) at baseline | −0.231 | 0.058 | −4.020 | <.001 |
| LVEF (%) at baseline | −0.107 | 0.130 | −0.280 | 0.410 |
| DDD (per day) at baseline | −4.933 | 2.432 | −2.030 | 0.044 |
| DDD change over a period of 1 year | | | | |
| Decrease (vs. no change) | −17.386 | 2.424 | −7.170 | <.001 |
| Increase (vs. no change) | 16.192 | 2.738 | 5.910 | <.001 |

AVF: arteriovenous fistula; AVG: arteriovenous graft; BMI: body mass index; CRP: C-reactive protein; DDD: defined daily dose; LVEF: left ventricular ejection fraction; LVMI: left ventricular mass index; PTH: parathyroid hormone; RAS: renin-angiotensin system; SE: standard error of β; β: regression coefficient. The covariates ‘decrease’, ‘no change’, and ‘increase’ in DDD were included in the model. The covariate ‘No change in DDD’ was used as the reference value.
than that observed in a multicenter observational study (88%) [27]. It remains to be confirmed whether these results are confirmed in HD patients who are elderly or present a higher usage of antihypertensive drugs.

Although it is unclear whether persistent extracellular fluid retention without obvious findings of volume overload can still cause LVH progression when the BP is controlled through the use of antihypertensive drugs, we considered that fluid retention may be the most important contributing factor to LVMI progression in HD patients. Despite the importance of achieving an appropriate dry weight for BP control, the lack of a specific index for determining the appropriate volume status makes it challenging.

Our study revealed that a reduction in the use of antihypertensive drug use over a period of 1 year after HD initiation was correlated with a decrease in the cardiothoracic ratio on chest radiographs and a decreased dry weight. Furthermore, a decrease in the cardiothoracic ratio on chest radiographs was associated with a decrease in LVMI over a period of 1 year after HD initiation, suggesting that the euolemic state of an appropriate dry weight could be approximated in patients who showed a reduction in the cardiothoracic ratio on chest radiographs and decreased dry weight. However, we did not use other tools, including bioimpedance plethysmography [26,28], relative plasma volume monitoring [29,30], measurement of the inferior vena cava diameter [12,31,32], and concentrations of plasma natriuretic peptides [22], to measure the volume status. In our practice, these methods were not regularly used. Future studies should employ these methods to evaluate the precise volume status. Furthermore, volume overload does not always equate to hypertension, because several factors, such as arterial stiffness, high renin states, the osmotic effects of glucose, and the nonosmotic effects of sodium could lead to a complex interplay [33]. It should be evaluated in future studies by including information concerning these factors.

DDD is useful when patients use the same medications before and after an intervention, with changes only in the dose. However, it may not be appropriate when there are changes in other antihypertensive drugs of different potencies. Generally, patients included in this study received the same medications during the study period. Especially, in cases where we aimed to change the potency of antihypertensive drugs, we first changed the dose, and not administered other anti-hypertensive agents. Regardless of the approach, when we could not attain a lower blood pressure, we provided other types of antihypertensive drugs.

Only five (2.1%) patients received medications of different potencies during the study period. Especially, in three of these five patients, the medication changed from cilnidipine (10 mg) to nifedipine (20 mg), from cilnidipine (10 mg) to nifedipine (40 mg), and from cilnidipine (10 mg) to amlodipine (10 mg). However, all three patients received other RAS inhibitors. In the other two patients, the medication changed from losartan (25 mg) to valsartan (40 mg) and from losartan (25 mg) to olmesartan (20 mg). However, these two patients also received other calcium channel blockers. All five patients who were prescribed drugs of different antihypertensive potencies were included in the DDD increase group. Therefore, we considered that the aforementioned antihypertensive treatment changes might not have significantly influenced our results.

Our study had several limitations that are worth noting. First, although our work was, to a large extent, the most current study to examine the longitudinal changes in LVMI in HD patients, the sample size was small, and the observational period was short. Second, this study did not evaluate the difference in patient outcomes because of the short observation period. Larger longitudinal cohort studies should be performed to evaluate this issue. Third, because of the retrospective nature of the study, causal relationships between the reduction in the use of antihypertensive drugs and LVMI regression could not be determined. Fourth, LVMI was not assessed using cardiac magnetic resonance imaging (MRI), which can show the cardiac structures in detail [22,23,34]; therefore, our results should be validated by other studies using cardiac MRI. Fifth, those who exhibited LVMI regression over a period of 1 year demonstrated volume control and a possibility of improving uremic cardiomyopathy and anemia. However, our study did not precisely evaluate this possibility because of the study design employed.

Allowing for these methodological issues, our results suggested that in patients who had good BP control by receiving multiple antihypertensive drugs, reducing antihypertensive drug use as much as possible could be an important strategy to obtain strict volume control to attenuate LVH.

Our findings suggested that volume reduction, which leads to a decrease in the use of antihypertensive drugs, could be a therapeutic strategy for HD patients to prevent LVMI progression.

Acknowledgments

We are grateful to A. Nakata and K. Kobayashi for helping in the data collection and providing useful suggestions.
Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The authors confirm that the data supporting the findings of this study are available within this article and its supplementary materials (Supplementary Table 1).

References

[1] Pippias M, Jager KJ, Kramer A, et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2016;31(5):831–841.
[2] Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998;11(5):239–245.
[3] Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001;12(5):1079–1084.
[4] Mostovaya IM, Bots ML, van den Dorpel MA, et al. Left ventricular mass in dialysis patients, determinants and relation with outcome. Results from the convective transport study (CONTRAST). PLoS One. 2014;9(2):e84587.
[5] Di Lullo L, Gorini A, Russo D, et al. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 2015;5(4):254–266.
[6] Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. Jama. 2004;292(19):2350–2356.
[7] Zoccali C, Mallamaci F, Tripepi G, et al. Prediction of left ventricular geometry by clinic, predialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens. 1999;17(12):1751–1758.
[8] Foley RN, Curtis BM, Randell EW, et al. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol. 2010;5(5):805–813.
[9] Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States Waves 3 and 4 Study. Kidney Int. 2002;62(5):1784–1790.
[10] Conlon PJ, Walshe JJ, Heinle SK, et al. Predialysis systolic blood pressure correlates strongly with mean 24-h systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol. 1996;7(12):2658–2663.
[11] Ok E, Asci G, Chazot C, et al. Controversies and problems of volume control and hypertension in hemodialysis. Lancet. 2016;388(10041):285–293.
[12] Katsaraki KS, Nisell J, Randmaa I, et al. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. Am J Kidney Dis. 1997;30(4):459–465.
[13] Ozkahya M, Ok E, Toz H, et al. Long-term survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Transplant. 2006;21(12):3506–3513.
[14] Meral K, Murat T, Mehmet O, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant. 2009;24(3):956–962.
[15] Takeda A, Toda T, Fuji T, et al. Can predialysis hypertension prevent intradialytic hypotension in hemodialysis patients? Nephron Clin Pract. 2006;103(4):c137–c143.
[16] Hirakata H, Nitta K, Inaba M, et al. Japanese society for dialysis therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial. 2012;16(5):387–435.
[17] WHO Collaborating Centre for Drug Statistics Methodology. Daily defined dose: definition and general considerations [online]; [cited 2013 Mar 16]. Available from http://www.whocc.no/ddd/definition_and_general_considera/.
[18] Modolo R, de Faria AP, Ritter AMV, et al. Defined daily dose (DDD) and its potential use in clinical trials of resistant hypertension. Int J Cardiol. 2016; 202:515–516.
[19] Lang R, Bierig M, Devereux R, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–1463.
[20] Otterstad JE, Froeland G, St John Sutton M, et al. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J. 1997;18(3):507–513.
[21] Callisaya ML, Sharman JE, Close J, et al. Greater daily defined dose of antihypertensive medication increases the risk of falls in older people—a population-based study. J Am Geriatr Soc. 2014;62(8):1527–1533.
[22] Patel RK, Oliver S, Mark PB, et al. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin J Am Soc Nephrol. 2009;4(9):1477–1483.
[23] Sarak B, Wald R, Goldstein MB, et al. Relationship between changes in blood pressure and left ventricular mass over 1 year in end-stage renal disease. J Hypertens. 2017;35(8):1709–1716.
[24] Agarwal R, Metiku T, Tegegne GG, et al. Diagnosing hypertension by intradialytic blood pressure recordings. Clin J Am Soc Nephrol. 2008;3(5):1364–1372.
[25] Hur E, Usta M, Toz H, et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis. 2013;61(6):957–965.
[26] Agarwal R, Nissenson AR, Battle D, et al. Prevalence, treatment, and control of hypertension in chronic
hemodialysis patients in the United States. Am J Med. 2003;115(4):291–297.

[27] Onofriescu M, Hogas S, Voroneanu L, et al. Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. Am J Kidney Dis. 2014;64(1):111–118.

[28] Sinha AD, Light RP, Agarwal R. Relative plasma volume monitoring during hemodialysis AIDS the assessment of dry weight. Hypertension. 2010;55(2):305–311.

[29] Rodriguez HJ, Domenici R, Diroll A, et al. Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line. Kidney Int. 2005;68(2):854–861.

[30] Luik AJ, van Kuijk WH, Spek J, et al. Effects of hyper-volemia on interdialytic hemodynamics and blood pressure control in hemodialysis patients. Am J Kidney Dis. 1997;30(4):466–474.

[31] Agarwal R, Bouldin JM, Light RP, et al. Inferior vena cava diameter and left atrial diameter measure volume but not dry weight. Clin J Am Soc Nephrol. 2011;6(5):1066–1072.

[32] Joffy S, Rosner MH. Natriuretic peptides in ESRD. Am J Kidney Dis. 2005;46(1):1–10.

[33] Aghogho O, Christopher M. Volume is not the only key to hypertension control in dialysis patients. Nephron Clin Pract. 2012;120(3):173–177.

[34] Khangura J, Culleton BF, Manns BJ, et al. Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis. BMC Nephrol. 2010;11:13.